Personal Finance

Why Dynavax Technologies Shares Are Crashing 63% Today

Market Crash Getty Images Sinking Stock Chart Woes
Market Crash Getty Images Sinking Stock Chart Woes

Image source: Getty Images.

What happened

Following news that the FDA has rejected the company's hepatitis B vaccine, shares in Dynavax Technologies Corp. (NASDAQ: DVAX) are tumbling 63% at 2:30 p.m. Monday.

So what

Dynavax Technologies' investors were hoping that a large trial conducted by the company following the FDA's rejection of Heplisav-B in 2013 would clear the way for Heplisav-B to make it to market this year, but the agency dashed those hopes on Monday when it rejected Heplisav-B for a second time.

The FDA's decision on Heplisav-B isn't a total surprise. In April, the FDA asked the company for additional information that pushed back the agency's decision timeline from September to December, and in August, the FDA cancelled a key advisory committee meeting that would have discussed the company's application in more depth.

Dynavax's management thinks that it can provide requested information to the agency that supports a resubmission of its Heplisav-B application, but management doesn't appear confident that it's something they can do without some help from a deep-pocketed peer.

Now what

The FDA is requesting "information regarding several topics, including clarification regarding specific adverse events of special interest (AESIs), a numerical imbalance in a small number of cardiac events in a single study (HBV-23), new analyses of the integrated safety data base across different time periods, and post-marketing commitments."

The grocery list of requested items did include an admission by the agency that it has yet to get all the way through information provided by Dynavax in October. Included in that information was additional insight into the AESI and cardiac events questions.

While the agency may have some of the information it needs already, management's statement that they're seeking a partner suggests there's enough work to be done that there's still significant uncertainty over this drug's future. Since Heplisav-B has suffered multiple confidence-busting stumbles, there's little reason for investors to take on the risk of hoping for a different outcome in the future. For that reason, focusing on other money making ideas may be the smartest move.

Forget the 2016 Election: 10 stocks we like better than Dynavax Technologies

Donald Trump was just elected president, and volatility is up. But here's why you should ignore the election:

Investing geniuses Tom and David Gardner have spent a long time beating the market no matter who's in the White House. In fact, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Dynavax Technologies wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as ofNovember 7, 2016

Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him on Twitter where he goes by the handle @ebcapitalto see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Personal Finance Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More